Aevi Genomic Medicine Inc. (NASDAQ:GNMX) and scPharmaceuticals Inc. (NASDAQ:SCPH), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation of the two firms.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aevi Genomic Medicine Inc. | N/A | 0.00 | 54.95M | -0.43 | 0.00 |
| scPharmaceuticals Inc. | 6 | 0.00 | 11.81M | -1.59 | 0.00 |
Demonstrates Aevi Genomic Medicine Inc. and scPharmaceuticals Inc. earnings per share, top-line revenue and valuation.
Profitability
Table 2 shows us the return on equity, net margins and return on assets of both businesses.
| Net Margins | Return on Equity | Return on Assets | |
| Aevi Genomic Medicine Inc. | 31,435,926,773.46% | -264.5% | -178.4% |
| scPharmaceuticals Inc. | 185,400,313.97% | -36.7% | -30.6% |
Liquidity
Aevi Genomic Medicine Inc.’s Current Ratio and Quick Ratio are 1.9 and 1.9 respectively. The Current Ratio and Quick Ratio of its competitor scPharmaceuticals Inc. are 8.5 and 8.5 respectively. scPharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to Aevi Genomic Medicine Inc.
Institutional & Insider Ownership
Aevi Genomic Medicine Inc. and scPharmaceuticals Inc. has shares held by institutional investors as follows: 6.4% and 60.3%. About 42.43% of Aevi Genomic Medicine Inc.’s share are held by insiders. On the other hand, insiders held about 0.1% of scPharmaceuticals Inc.’s shares.
Performance
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
| Performance (W) | Performance (M) | Performance (Q) | Performance (HY) | Performance (Y) | Performance (YTD) | |
| Aevi Genomic Medicine Inc. | -9.48% | -7.97% | -32.82% | -17.4% | -83.14% | -76.4% |
| scPharmaceuticals Inc. | 10.06% | 79.01% | 80.12% | 54.67% | 25% | 54.26% |
For the past year Aevi Genomic Medicine Inc. had bearish trend while scPharmaceuticals Inc. had bullish trend.
Summary
On 5 of the 9 factors scPharmaceuticals Inc. beats Aevi Genomic Medicine Inc.
Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohnÂ’s disease. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.
scPharmaceuticals Inc., biopharmaceutical company, engages in the development and commercialization of transformative pharmaceutical products. The company's under development products are for heart failure and infectious diseases that include Furoscix that is for treatment of worsening or decompensated heart failure outside of the inpatient setting. scPharmaceuticals Inc. formerly known as scPharmaceuticals LLC. and changed its name to scPharmaceuticals Inc. in March 2014. The company was founded 2013 and is based in Burlington, Massachusetts.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
